<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322201</url>
  </required_header>
  <id_info>
    <org_study_id>CHULC.CI.450.2019</org_study_id>
    <nct_id>NCT04322201</nct_id>
  </id_info>
  <brief_title>Continuous Passive Paracentesis for Intra-abdominal Hypertension</brief_title>
  <acronym>COPPTRIAHL</acronym>
  <official_title>Continuous Passive Paracentesis Versus Large Volume Paracentesis in the Prevention and Treatment of Intra-abdominal Hypertension and Abdominal Compartment Syndrome in the Critically Ill Cirrhotic Patient With Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Hospitalar de Lisboa Central</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis patients in Intensive Care present intra-abdominal hypertension and this is
      an independent risk factor for increased organ disfunction and mortality.

      Patients will be randomized into intermittent or continuous passive paracentesis and the
      clinical results of these two strategies for preventing and treating intra-abdominal
      hypertension will compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intra-abdominal hypertension is an independent risk factors for increased mortality in
      Intensive Care patients and is highly prevalent in the critically ill cirrhotic patient. This
      study compares two strategies in minimizing intra-abdominal pressure and optimizing abdominal
      perfusion pressure in the prevention and treatment of intra-abdominal hypertension associated
      morbidity and mortality. Critically ill cirrhotic patients will be allocated into a
      standard-of-care large-volume paracentesis group (control) and a continuous passive
      paracentesis (intervention) group using randomization. Results will assess renal function and
      multi-organ function using standard clinical scales and vital outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function - creatinine clearance</measure>
    <time_frame>intensive care stay up to 7 days</time_frame>
    <description>estimated and measured creatinine clearance (mL/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function - urine output</measure>
    <time_frame>intensive care stay up to 7 days</time_frame>
    <description>measured urine output (mL/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function - renal replacement therapy</measure>
    <time_frame>intensive care stay up to 7 days</time_frame>
    <description>number of renal replacement therapy days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-organ disfunction</measure>
    <time_frame>intensive care stay up to 7 days</time_frame>
    <description>Clinical multi-organ disfunction as assessed by severity scores: Sequencial Organ Failure Assessement (SOFA) and Chronic Liver Failure-SOFA (CLIF-SOFA). Both scores range [0-24] and higher scores reflect more severe organ dysfunctions and worse outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality rate</measure>
    <time_frame>from admission into the ICU up to 30 days onwards</time_frame>
    <description>Mortality rate until discharge from the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in hospital Mortality rate</measure>
    <time_frame>from admission into the ICU up to 60 days onwards</time_frame>
    <description>Mortality rate until discharge from hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days Mortality rate</measure>
    <time_frame>from admission into the ICU up to 30 days onwards</time_frame>
    <description>Mortality rate up to 30 days from ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergent liver transplant rate</measure>
    <time_frame>from admission into the ICU up to 28 days onwards</time_frame>
    <description>liver transplant rate up to 28 days after ICU admission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ICU length-of-stay</measure>
    <time_frame>from admission into the ICU up to 28 days</time_frame>
    <description>days in Intensive Care Unit</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length-of-stay</measure>
    <time_frame>from admission into the ICU up to 60 days onwards</time_frame>
    <description>days of Hospital stay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ascites Hepatic</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Hypertension, Intraabdominal</condition>
  <condition>Critical Illness</condition>
  <condition>Paracentesis</condition>
  <arm_group>
    <arm_group_label>Intervention group - Continuous passive paracentesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group - Large volume paracentesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter</intervention_name>
    <description>Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care</description>
    <arm_group_label>Intervention group - Continuous passive paracentesis</arm_group_label>
    <other_name>continuous passive paracentesis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided intermittent large-volume paracentesis</intervention_name>
    <description>Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter</description>
    <arm_group_label>Control group - Large volume paracentesis</arm_group_label>
    <other_name>intermittent passive paracentesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis diagnosis with ascites

          -  ICU admission for medical reason

        Exclusion Criteria:

          -  prior liver transplant

          -  haemorrhagic ascites

          -  extreme severity: CLIF-SOFA number of organ failures 5 or more

          -  less than 24 hours of ICU stay

          -  Any of the following conditions at 24 hours of ICU stay:

             i. Hemorrhagic shock with active uncontrolled bleeding ii. Refractory shock
             (MAP&lt;60mmHg) with multiple vasopressors iii. Predictably short ICU stay (&lt;72 hours)
             iv. Therapeutic futility determined by the medical staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui A Pereira, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar de Lisboa Central</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui A Pereira, MD, MSc</last_name>
    <phone>+351 934341322</phone>
    <email>rui.m.pereira@chlc.min-saude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Pereira-da-Silva, MD, PhD</last_name>
    <phone>213596402</phone>
    <phone_ext>51402</phone_ext>
    <email>centro.investigacao@chlc.min-saude.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCIP7 - Centro Hospitalar Universit√°rio de Lisboa Central</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-099</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui A Pereira, MD, MSc</last_name>
      <phone>+351 934341322</phone>
      <email>rui.m.pereira@chlc.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Rui A Pereira, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuno S Germano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Caldwell J, Edriss H, Nugent K. Chronic peritoneal indwelling catheters for the management of malignant and nonmalignant ascites. Proc (Bayl Univ Med Cent). 2018 Jun 1;31(3):297-302. doi: 10.1080/08998280.2018.1461525. eCollection 2018 Jul. Review.</citation>
    <PMID>29904292</PMID>
  </reference>
  <reference>
    <citation>Kyoung KH, Hong SK. The duration of intra-abdominal hypertension strongly predicts outcomes for the critically ill surgical patients: a prospective observational study. World J Emerg Surg. 2015 May 30;10:22. doi: 10.1186/s13017-015-0016-7. eCollection 2015.</citation>
    <PMID>26056530</PMID>
  </reference>
  <reference>
    <citation>Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, Duchesne J, Bjorck M, Leppaniemi A, Ejike JC, Sugrue M, Cheatham M, Ivatury R, Ball CG, Reintam Blaser A, Regli A, Balogh ZJ, D'Amours S, Debergh D, Kaplan M, Kimball E, Olvera C; Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013 Jul;39(7):1190-206. doi: 10.1007/s00134-013-2906-z. Epub 2013 May 15.</citation>
    <PMID>23673399</PMID>
  </reference>
  <results_reference>
    <citation>Al-Dorzi HM, Tamim HM, Rishu AH, Aljumah A, Arabi YM. Intra-abdominal pressure and abdominal perfusion pressure in cirrhotic patients with septic shock. Ann Intensive Care. 2012 Jul 5;2 Suppl 1:S4. doi: 10.1186/2110-5820-2-S1-S4. Epub 2012 Jul 5.</citation>
    <PMID>22873420</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Ascites</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Intraabdominal Hypertension</keyword>
  <keyword>Paracentesis</keyword>
  <keyword>Puncture and Drainage</keyword>
  <keyword>Critical Illness</keyword>
  <keyword>acute-on-chronic liver failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intra-Abdominal Hypertension</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

